Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...

Medicaid expansion is associated with lower 2- and 4-year mortality among patients with resectable non-small cell lung cancer ...

Wendy Brooks, a patient with extensive-stage small cell lung cancer, and her husband and care partner, Larry Brooks, sat down ...

For patients with extensive-stage small cell lung cancer (ES-SCLC), administration of immune checkpoint inhibitor (ICI) ...

SINGAPORE,First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients.

The third generation EGFR TKI targets EGFR mutant NSCLC, showing improved progression free survival and fewer adverse events ...

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first ...

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States.Over 80% of lung ...

Receiving anticancer immunotherapy earlier in the day may help individuals with cancer live longer. That's according to a ...

A Birmingham-based doctor has shared the most "unusual" signs of lung cancer, after revealing it has one of the lowest ...

Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in ...